Myozyme Temporary Access Program
ID Number 08-0453Principal Investigator(s)
Mark A Sivak
Department(s) or Division(s)
The purpose of this study is to provide adult patients with Pompe disease in the United States (US) access to investigational Aglucosidase Alfa for a limited time until it is approved for commercial use by the Food and Drug Administration (FDA) and sufficient supply is available.
Recruiting Patients: Yes